LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Pliant Therapeutics Inc

Cerrado

1.53 -3.77

Resumen

Variación precio

24h

Actual

Mínimo

1.53

Máximo

1.62

Métricas clave

By Trading Economics

Ingresos

13M

-43M

Margen de beneficio

-2,190.837

Empleados

171

EBITDA

17M

-42M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+68.55% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.8M

106M

Apertura anterior

5.3

Cierre anterior

1.53

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Pliant Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 sept 2025, 22:39 UTC

Adquisiciones, fusiones, absorciones

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept 2025, 16:43 UTC

Principales Movimientos del Mercado

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept 2025, 16:42 UTC

Principales Movimientos del Mercado

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept 2025, 16:35 UTC

Principales Movimientos del Mercado

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept 2025, 22:48 UTC

Charlas de Mercado

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Expects Commercial Launch in 2029

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 sept 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept 2025, 19:14 UTC

Charlas de Mercado

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept 2025, 18:16 UTC

Charlas de Mercado

Gold Powers to New High -- Market Talk

15 sept 2025, 18:05 UTC

Charlas de Mercado

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept 2025, 17:50 UTC

Adquisiciones, fusiones, absorciones

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept 2025, 17:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 17:10 UTC

Charlas de Mercado

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept 2025, 16:52 UTC

Charlas de Mercado

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

68.55% repunte

Estimación a 12 meses

Media 2.68 USD  68.55%

Máximo 4 USD

Mínimo 1.7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

1

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat